home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

193.81 -7.37 (-3.66%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

57 58 Next >

Expert Ratings for Biogen ↗

November 09, 2023

Via Benzinga

Thoughts For Thursday: Staying On Top - Barely ↗

November 09, 2023

The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago.

Via Talk Markets

Biogen (BIIB) Q3 2023 Earnings Call Transcript ↗

November 08, 2023

BIIB earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides ↗

November 08, 2023

Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 08, 2023

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

November 06, 2023

Via Benzinga

Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years ↗

November 01, 2023

Via Benzinga

Assessing Biogen's Performance Against Competitors In Biotechnology Industry ↗

October 30, 2023

Via Benzinga

$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today ↗

October 18, 2023

Via Benzinga

Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics ↗

November 08, 2023

Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023.

Via Talk Markets

US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings ↗

November 08, 2023

Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into...

Via Benzinga

Topics Economy

Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount ↗

November 08, 2023

The company shares in the profits and sales related to Alzheimer's treatment, Leqembi.

Via Investor's Business Daily

3 Biotech Moonshots to Bet on the Future of Health ↗

November 06, 2023

Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.

Via InvestorPlace

Topics Intellectual Property

Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry ↗

October 16, 2023

Via Benzinga

BIIB Stock Price Analysis: To Bet Or To Fold The Cards ↗

October 14, 2023

Massachusetts-based Biogen (BIIB) is a global biotechnology leader, researching and developing therapies for debilitating diseases impacting the central nervous system.

Via Talk Markets

Biogen Appoints Monish Patolawala to its Board of Directors

November 06, 2023

Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation

From Biogen Inc.

Via GlobeNewswire

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment ↗

October 26, 2023

Both companies are working on under-the-skin injections for Alzheimer's treatment.

Via Investor's Business Daily

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On

October 25, 2023

From Biogen Inc.

Via GlobeNewswire

Analyst Ratings for Biogen ↗

October 11, 2023

Via Benzinga

Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease ↗

October 25, 2023

Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau,

Via Benzinga

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

October 25, 2023

From Biogen Inc.

Via GlobeNewswire

An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week ↗

October 24, 2023

Another RSI Buy In a post last month, we wrote about the power of RSI (Relative Strength Index) as a technical indicator (Relative Strength Index) in relation to Stitch Fix, Inc. (NASDAQ: SFIX)

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 23, 2023

Via Benzinga

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

October 19, 2023

From Biogen Inc.

Via GlobeNewswire

3 Struggling Stocks Investors Shouldn't Buy on the Dip ↗

October 18, 2023

These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.

Via The Motley Fool

Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage ↗

October 13, 2023

The U.S.

Via Benzinga

7 Low-Volatility Stocks to Buy if You’re a Concerned Investor ↗

October 11, 2023

With market and economic conditions worrying many investors, it may be time to consider the virtues of low-volatility stocks.

Via InvestorPlace

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...

Via Benzinga

LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly ↗

October 10, 2023

Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ:

Via Benzinga

Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio ↗

October 07, 2023

Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen...

Via Talk Markets

Topics Initial Public Offering

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com